Rare Risk of Blindness Linked to Popular Weight Loss Drugs: Ozempic and Wegovy
Popular weight loss and diabetes medications Ozempic and Wegovy have been linked to a rare eye condition that can cause sudden vision loss. The condition, called non-arteritic anterior ischemic optic neuropathy (NAION), is different from diabetic retinopathy, and researchers and regulators are still studying how strong the connection is. Here is what patients should know.
The study and its findings
The concern that drew national attention centers on non-arteritic anterior ischemic optic neuropathy. Research from Harvard’s Mass Eye and Ear, published in JAMA Ophthalmology in 2024, found that patients prescribed semaglutide, the active ingredient in both Ozempic and Wegovy, appeared to have a higher rate of NAION than comparable patients who were not.
NAION is a sudden, usually painless loss of vision caused by reduced blood flow to the optic nerve, the cable that carries visual signals from the eye to the brain. It is not the same as diabetic retinopathy, which is damage to the blood vessels of the retina from high blood sugar. NAION most often affects one eye, can come on overnight, and in most cases the vision loss is permanent.
It is important to keep the findings in perspective. The studies describe an association, not proof that the medication directly causes NAION, and even where the risk is raised, the number of people affected is small.
What regulators and researchers have said
Since the first reports, health authorities have taken the question seriously while urging patients not to panic. The U.S. Food and Drug Administration opened a safety review in 2024, and in June 2025 the European Medicines Agency concluded that NAION is a “very rare” side effect of semaglutide and updated the medication’s product information to reflect it.
Follow-up studies have reached mixed conclusions. Several large patient databases have found the risk of NAION elevated among semaglutide users, while some pooled analyses found no statistically significant increase. Researchers broadly agree on two points: any added risk is small in absolute terms, and the benefits of these medications for diabetes and weight management are well established. Study into the connection is ongoing.
Call now or book your appointment online.
Recommendations for Ozempic or Wegovy users
If you take Ozempic or Wegovy, or are considering them, a few sensible steps can help protect your eye health:
- Treat any sudden change in vision as an emergency. Sudden, painless vision loss or a dark or missing area in one eye should be evaluated by an eye specialist or emergency room right away.
- Keep up with regular eye exams, which is especially important if you have diabetes.
- Manage vascular risk factors such as high blood pressure and sleep apnea with your primary care doctor, since these are linked to NAION.
- Never stop a prescribed medication on your own. Talk with the doctor who prescribed it so you can weigh the benefits against this rare risk for your situation.
Stay informed about your eye health
The link between semaglutide and NAION adds an important consideration to the conversation about these popular medications, but it does not erase their proven benefits for weight loss and diabetes management. For most people, the risk to vision is rare. Staying informed, keeping regular eye exams, and knowing the warning signs of sudden vision loss are the best ways to protect your sight while benefiting from treatment. If you have diabetes, your eye doctor can also monitor your retina for diabetic eye disease, which is a separate condition.
For more detailed information, please refer to the original CNN article: “Ozempic, Wegovy linked to rare risk of blindness.”
Why trust your eyes to the Assil Gaur Eye Institute?
The Assil Gaur Eye Institute (AGEI) has assembled a team of top ophthalmology specialists from around the country who offer patients of all ages the highest quality healthcare in the United States.
AGEI is nationally recognized for its compassionate, patient-centric care, commitment to pioneering advances in ophthalmology, genetic testing, and congenital anomalies, and dedication to supporting patients’ health and well-being.
AGEI ophthalmologists have participated in dozens of FDA clinical trials, either as lead investigators or as members of a multi-center team, testing new ophthalmological devices and surgical techniques.
To request a consultation, please make an appointment online or call us at 866-945-2745.
We are conveniently located for patients throughout Southern California and the Los Angeles area in or near Beverly Hills, Santa Monica, West Los Angeles, West Hollywood, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, and Downtown Los Angeles.
Frequently Asked Questions About Ozempic, Wegovy, and Vision Loss
What eye condition is actually linked to Ozempic and Wegovy?
The condition highlighted in recent research is NAION, or non-arteritic anterior ischemic optic neuropathy. It is a sudden, usually painless loss of vision caused by reduced blood flow to the optic nerve, and it is different from diabetic retinopathy. Regulators consider it a very rare potential side effect of semaglutide, the active ingredient in both drugs.
What are the warning signs of NAION?
NAION typically causes sudden, painless vision loss or a dark or missing area in the vision of one eye, often noticed upon waking. It usually affects one eye at a time. Any sudden change in vision is a medical emergency: seek care from an eye specialist or emergency room right away.
How common is this risk?
It is rare. European regulators classify NAION as a “very rare” side effect, and while several large studies found the risk elevated among semaglutide users, the absolute number of people affected remains low. Research is still ongoing, and not all studies agree on the size of the risk.
Who is most at risk
The risk appears higher in people who already have vascular risk factors such as diabetes, high blood pressure, or sleep apnea, and in those with a particular optic nerve shape known as a “crowded” or “disc at risk” nerve. People who have had NAION in one eye are also at greater risk in the other.
Should I stop taking Ozempic or Wegovy?
Do not stop these medications on your own. For many people they offer significant, well-documented benefits for diabetes and weight management, and the eye risk is rare. If you are concerned, talk with the doctor who prescribed the medication so you can weigh the benefits and risks for your specific situation.
Is the vision loss from NAION reversible?
In most cases NAION causes permanent vision loss, and there is no proven treatment to restore the lost vision. This is why prompt evaluation of any sudden vision change matters, both to confirm the cause and to protect the other eye.
Do other weight-loss or diabetes drugs carry the same risk?
The current signal centers on semaglutide, the ingredient in Ozempic and Wegovy. Evidence on other GLP-1 medications, such as tirzepatide (Mounjaro and Zepbound), is more limited, and researchers are still studying whether the risk extends to them.
Does semaglutide affect diabetic retinopathy?
This is a separate concern from NAION. Rapid improvement in blood sugar can temporarily worsen existing diabetic retinopathy, a pattern seen with several diabetes treatments, which is one reason regular retinal exams are important when starting or changing therapy. If you have diabetes, your eye doctor can monitor your retina alongside your treatment.
-
Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology, 2024.
-
European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 6, 2025.
-
McPhillips, D. Popular weight loss and diabetes drugs are linked to an increased risk of a rare form of blindness. CNN Health, July 3, 2024.
Written by The AGEI Educational Team
Medically Reviewed by Dr. Svetlana Pilyugina
